Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21611490 | 0.94 | ESR2 (0.52) | NR1H2GPR119ESR2ALDH1A1MAPT | |
| SCHEMBL21611514 | 0.94 | NR1H2 (0.53) | NR1H2GPR119ESR2ALDH1A1MAPT | |
| SCHEMBL21611545 | 0.84 | NR1H2 (0.49) | NR1H2GPR119ESR2HDAC1MAPT | |
| SCHEMBL21611381 | 0.80 | GPR119 (0.42) | GPR119ALDH1A1MAPTCYP3A4LMNA | |
| SCHEMBL23646517 | 0.79 | NR1H2 (0.62) | NR1H2GPR119ESR2MAPTCYP3A4 | |
| SCHEMBL21611636 | 0.79 | NR1H2 (0.56) | NR1H2GPR119ESR2MAPTCYP3A4 | |
| SCHEMBL21611588 | 0.77 | ALDH1A1 (0.46) | GPR119ALDH1A1MAPTLMNA | |
| SCHEMBL23797939 | 0.77 | HSPB1 (0.46) | NR1H2ESR2ALDH1A1HDAC1MAPT | |
| SCHEMBL21611586 | 0.77 | GPR119 (0.46) | GPR119ALDH1A1MAPTCYP3A4 | |
| SCHEMBL24761144 | 0.76 | ESR2 (0.56) | NR1H2ESR2ALDH1A1HDAC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221785-A1 | AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | VERNALIS (R&D) LTD (GB) | 2021-07-22 | — | — | US | disclosed |
| EP-3818054-A1 | AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020008013-A1 | AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221785-A1 | AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DHFR, QDPR, DPYD | NR1H2 3326/4885GPR119 529/4885ESR2 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.